WebMar 12, 2024 · Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Rating) CEO Thomas J. Schuetz acquired 10,000 shares of the stock in a transaction on Friday, March 10th. The shares were acquired at an average price of $3.37 per share, for a total transaction of $33,700.00. Following the acquisition, the chief executive officer now owns 6,021,873 … WebApr 12, 2024 · Report Shows Expected Uptick in Layoffs and Collaboration across BioPharma. 3/13/2024. A recent report released by accounting and consulting firm BDO showed that over the course of 2024, 13% of life sciences companies may turn to layoffs in response to uncertain economic conditions.
Compass Therapeutics Announces $80 Million Private Placement
WebCompany profile for Compass Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. View detailed CMPX description & address. WebSep 20, 2024 · Although the company is showing a strong front, Compass’ stocks took another tumble after the news of its latest layoffs. Compass stock opened at $2.68 per … history backup settings
Compass CEO issues email explaining company layoffs
WebOct 11, 2024 · BOSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer ... WebMar 24, 2024 · SVB Securities analyst Andrew Berens maintained a Buy rating on Compass Therapeutics (CMPX - Research Report) on November 9 and set a price target of $11.00. The company's shares closed last ... WebSep 20, 2024 · Compass does another big round of layoffs Brokerage notes $23M-$26M in severance costs, says "significant portion" of cuts hit product, engineering team National / history back in javascript